CN115925896A

CN115925896A - Novel coronavirus RBD specific monoclonal antibody and application

Info

Publication number: CN115925896A
Application number: CN202210906254.4A
Authority: CN
Inventors: 韩晓建; 王应明; 胡超; 李婷婷; 王建为; 李胜龙; 金艾顺
Original assignee: Chongqing Medical University
Current assignee: Chongqing Medical University
Priority date: 2020-08-19
Filing date: 2020-08-19
Publication date: 2023-04-07
Also published as: CN111909263B; WO2022037616A1; CN117736313A; CN116813760A; CN111909263A; CN117003862A; CN114920832A; CN114920832B

Abstract

The invention belongs to the technical field of monoclonal antibodies, and particularly discloses a novel coronavirus RBD specific monoclonal antibody and application of the novel coronavirus RBD specific monoclonal antibody. The invention has important scientific significance and application prospect for the prevention and clinical treatment of diseases caused by the novel coronavirus SARS-CoV-2 and the research and development of diagnostic reagents.

Description

Novel coronavirus RBD specific monoclonal antibody and application

Technical Field

The invention belongs to the technical field of monoclonal antibodies, and particularly relates to a novel coronavirus RBD specific monoclonal antibody and application thereof.

Background

Antibodies are immunoglobulin molecules composed of four polypeptide chains, including two heavy chains (H chains) and two light chains (L chains). The H chain consists of a heavy chain variable region (VH) and a heavy chain constant region consisting of three regions, CH1, CH2 and CH 3. The L chain consists of an L variable region (VL) and a light chain constant region consisting of a CL region. VH and VL can be further divided into hypervariable regions known as Complementarity Determining Regions (CDRs) and conserved regions known as Framework Regions (FR) that alternate.

The research shows that: the novel coronavirus (SARS-CoV-2) has four major structural proteins, the spike protein (S protein), the nucleocapsid protein (N protein), the membrane protein (M protein), and the envelope protein (E protein), respectively, wherein the S protein has two subunits: s1 and S2, receptor Binding Sites (RBDs) are located on the S1 subunit, and their primary function is to recognize host cell surface receptors, mediating fusion with host cells.

Chinese invention patent application with application publication No. CN111303280A discloses a fully human monoclonal antibody against SARS-CoV-2 with high neutralizing activity, which provides a fully human monoclonal antibody with a recognition region of S1 non-RBD region, but the blocking effect of the fully human monoclonal antibody on virus obtained by the above patent is limited because the novel coronavirus invading host cell is combined with ACE2 of the host cell through RBD, and the antibody cDNA obtained by marking plasma cell is reacted rapidly after the memory B cell is activated, compared with plasma cell, so the memory B cell can induce faster than the initial reaction and stronger humoral immune response, and the humoral immune response induced by plasma cell is limited.

Disclosure of Invention

The invention aims to provide a novel coronavirus RBD specific monoclonal antibody which is directed to RBD and can trigger stronger humoral immune response and application thereof.

In order to achieve the above objects, the present invention provides a novel coronavirus RBD-specific monoclonal antibody, specifically, the heavy chain amino acid sequence of the antibody can be shown as SEQ ID NO. 1; the light chain amino acid sequence can also be shown as SEQ ID NO:2 (monoclonal antibody 2-CQTS 002). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 3; the light chain amino acid sequence can also be shown as SEQ ID NO:4 (mAb 3-CQTS 003). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 5; the light chain amino acid sequence can also be shown as SEQ ID NO:6 (mAb 5-CQTS 005). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 7; the light chain amino acid sequence can also be shown as SEQ ID NO:8 (mAb 6-CQTS 006). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 9; the light chain amino acid sequence may also be shown as SEQ ID NO:10 (mAb 7-CQTS 007). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 11; the light chain amino acid sequence can also be shown as SEQ ID NO:12 (monoclonal antibody 8-CQTS 008). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 13; the light chain amino acid sequence can also be shown as SEQ ID NO:14 (mAb 9-CQTS 009). The heavy chain amino acid sequence can also be shown as SEQ ID NO. 15; the light chain amino acid sequence can also be shown as SEQ ID NO:16 (monoclonal antibody 10-CQTS 010). The invention also provides the use of the above-mentioned novel coronavirus RBD-specific monoclonal antibody in the preparation of a reagent or vaccine or medicament for detecting or diagnosing SARS-CoV-2, wherein the medicament comprises the novel coronavirus RBD-specific monoclonal antibody as defined in any one of claims 1 to 8 and a pharmaceutically acceptable excipient, diluent or carrier; also provided are nucleic acid molecules encoding the novel coronavirus RBD-specific monoclonal antibodies described above; also provides an expression cassette, a recombinant vector, a recombinant bacterium or a transgenic cell line containing the nucleic acid molecule; also provides the application of the expression cassette, the recombinant vector, the recombinant bacterium or the transgenic cell line in the preparation of products.

The invention also provides a product which comprises the novel coronavirus RBD specific monoclonal antibody; the product is used in any one of the following (b 1) to (b 4): (b 1) binds to novel coronavirus SARS-CoV-2; (b 2) detecting binding of the novel coronavirus SARS-CoV-2; (b 3) binding to the S protein of the novel coronavirus SARS-CoV-2; (b 4) detecting the S protein of the novel coronavirus SARS-CoV-2.

Preferably, the novel coronavirus RBD-specific monoclonal antibody is obtained by sorting RBD-specific memory B cells and obtaining antibody variable region cDNA from mRNA of the RBD-specific memory B cells.

The principle and the beneficial effects of the invention are as follows:

(1) The monoclonal antibody provided by the invention has RBD specificity, and compared with a monoclonal antibody aiming at an S1 non-RBD region, the monoclonal antibody provided by the invention is combined with RBD, thereby providing wider application value for screening antibody drugs, diagnosing, preventing and treating novel coronavirus pneumonia.

(2) The monoclonal antibody provided by the invention is obtained by sorting RBD specific memory B cells, and compared with the prior art of sorting plasma cells, the monoclonal antibody prepared by the invention can trigger stronger humoral immune response. In addition, the invention only aims at RBD specific memory B cells to carry out subsequent RT-PCR, nested PCR and antibody function analysis, thereby greatly improving the specific binding capacity of the monoclonal antibody and the RBD.

Drawings

FIG. 1 is a cytometric map of memory B cells analyzed using flow cytometry;

FIG. 2 is a cell sorting graph of RBD specific memory B cells analyzed by flow cytometry;

FIG. 3 is a gel electrophoresis of the PCR product of the antibody gene of a single cell;

FIG. 4 is a photograph of agarose gel electrophoresis following PCR amplification of an antibody gene expression cassette containing the CMV promoter, WPRE-gamma or WPRE-kappa element;

FIG. 5 is a graph showing the results of an experiment on the specificity of RBD.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1

This example provides a novel coronavirus RBD specific monoclonal antibody, whose heavy chain amino acid sequence is shown in SEQ ID NO. 1; the light chain amino acid sequence is shown as SEQ ID NO. 2.

The embodiment also provides the application of the novel coronavirus RBD specific monoclonal antibody in the preparation of a reagent or a medicament for detecting or diagnosing SARS-CoV-2.

In practical production, the RBD-specific monoclonal antibody obtained in this example can be used to prepare a nucleic acid molecule, or an expression cassette, a recombinant vector, a recombinant bacterium or a transgenic cell line containing the nucleic acid molecule, or a pharmaceutical composition comprising the novel coronavirus RBD-specific monoclonal antibody and a pharmaceutically acceptable excipient, diluent or carrier.

In application, the related product prepared by the RBD specific monoclonal antibody obtained in the embodiment can have the following application of any one of (b 1) to (b 4): (b 1) binds to novel coronavirus SARS-CoV-2; (b 2) detecting binding of the novel coronavirus SARS-CoV-2; (b 3) binding to the S protein of the novel coronavirus SARS-CoV-2; (b 4) detecting the S protein of the novel coronavirus SARS-CoV-2.

Examples 2 to 8

Examples 2-8 differ from example 1 in that: the amino acid sequences of the RBD-specific monoclonal antibodies were varied, and the amino acid sequences of examples 2-8 are shown in the following table:

experimental group	Heavy chain amino acid sequence	Light chain amino acid sequence
			Example 1 CQTS002	SEQ ID NO:1	SEQ ID NO:2
Example 2 CQTS003	SEQ ID NO:3	SEQ ID NO:4
			Example 3 CQTS005	SEQ ID NO:5	SEQ ID NO:6
Example 4 CQTS006	SEQ ID NO:7	SEQ ID NO:8
			Example 5 CQTS007	SEQ ID NO:9	SEQ ID NO:10
Example 6 CQTS008	SEQ ID NO:11	SEQ ID NO:12
			Example 7 CQTS009	SEQ ID NO:13	SEQ ID NO:14
Example 8 CQTS010	SEQ ID NO:15	SEQ ID NO:16

The RBD-specific monoclonal antibodies provided in examples 1-8 above were obtained by the following method: firstly, single RBD specific memory B cells are obtained by separating peripheral blood of a rehabilitation patient with the novel coronavirus pneumonia, then mRNA of the RBD specific memory B cells is obtained, then an antibody variable region gene expression box is constructed by RT-PCR and nested PCR, then the antibody variable region gene expression box is transduced into 293T cells to express an antibody, supernatant is collected, the RBD specificity of the supernatant is detected by an ELISA method, and RBD specific monoclonal antibodies are obtained by screening.

The method specifically comprises the following steps:

s1, collecting peripheral blood of a plurality of novel coronavirus pneumonia rehabilitation patients, separating to obtain PBMC, and freezing and storing in a refrigerator at-80 ℃ for later use.

S2, firstly removing Dead cells of PBMC obtained in the S1 by adopting Dead cell removing Dye (Dead Dye), then adopting CD19, mIg-G, mIg-D and S-RBD to Dye and mark live RBD in the PBMC with high specificity and high binding capacity for memory B cells, and screening memory B cells specific to the RBD; specific memory B cells were sorted using a flow cytometric sorter onto 96-well plates, one specific memory B cell per well, and frozen at-80 ℃ in a freezer for use.

Specifically, the preferred concentration range of the Dead Dye staining in this embodiment is 1-2 μ g/mL, and the preferred concentration range of the Dead Dye staining in this embodiment is 1.5 μ g/mL; CD19 is a B cell marker produced by Biolegend and is stained at a concentration in the range of 1-2. Mu.g/mL, and in this example, CD19 is preferably stained at a concentration of 1.5. Mu.g/mL. mIg-G is a B cell surface receptor produced by Biolegend, and the concentration range of the mIg-G during staining is 1-2 mu G/mL, and the concentration of the mIg-G during staining is 1.5 mu G/mL in the embodiment; mIg-D is B cell surface receptor produced by Biolegend, and the concentration range when staining is 1-2 μ g/mL, and the concentration when staining mIg-D is 1.5 μ g/mL is preferred in the embodiment; S-RBD is a novel coronavirus produced by sinobiological, protein receptor domain, and the concentration range when staining is 1-2. Mu.g/mL, and the concentration when staining S-RBD is 1.5. Mu.g/mL is preferred in this example.

Cell sorting of PBMC by CD19, mIg-G, mIg-D and S-RBD for RBD-specific memory B cell sorting by flow cytometry the cell sorting profiles for B cells with memory specific to S-RBD are shown in FIGS. 1 and 2, where

Batch ID

0428, 0505, 0522, 0528 in FIG. 2 are screening batches. The principle of screening RBD-specific memory B cells by using CD19, mIg-G, mIg-D and S-RBD in this example is as follows: PBMC were stained with Dead cell stain (Dead Dye), B cell marker CD19, memory B cell markers mIg-G positive and mIg-D negative, and memory B cells expressing RBD-specific IgG, then the CD19 cell population was divided from the cell population using a flow cytometer, and mIg-G was divided from the CD19 positive cell population ⁺ mIg-D ^- Cell population from mIg-G ⁺ mIg-D ^- Dividing the cell group into RBD positive memory B cells, and sorting the RBD positive memory B cells by a flow cytometric sorter.

S3, sorting to obtain mRNA of a single RBD specific memory B cell, and performing RT-PCR amplification to obtain antibody variable region cDNA. Specifically, when RT-PCR is used to amplify cDNA in the variable region of the antibody, the primer front segment of the primer designed in this example is designed with a universal Leader (see primer sequence listing one and primer sequence listing two), which effectively improves the amplification rate of the antibody gene, and the experimental result is shown in fig. 3.

S4, amplifying the cDNA of the antibody variable region obtained from the S1-S3 by adopting nested PCR to construct an antibody variable region gene expression cassette.

S3 and S4 are performed by the following six sections in total: (1) extracting mRNA of RBD specific memory B cells; (2) single cell mRNA Reverse Transcription (RT); (3) adding G tail (TDT); (4) first round PCR (1 st PCR); (5) second round PCR (2 ndPCR); (6) BCR-ORF PCR amplification construction gene expression cassette; (7) CMV, WPRE-gamma/kappa/l fragment amplification and CMV, BCR-V gamma/kappa/l ((6) product), WPRE-gamma/kappa/l Overlap PCR (Overlap PCR) pre-connection; (8) BCR-gamma ORF, BCR-kappa ORF and BCR-lPCR amplification.

The preparation and reaction conditions of each part of reaction liquid are as follows:

(1) Using Dynabeads ^TM mRNA DIRECT ^TM The single cell mRNA extraction is carried out by a Purification Kit (Thermo Fisherscientific), and the method specifically comprises the following steps:

(1) centrifuging: taking out the 96-well plate with the single RBD specific memory B cell from a refrigerator at the temperature of-80 ℃, and centrifuging the plate at the speed of 600 Xg for 30s to ensure that the cell is centrifuged at the bottom of the well;

(2) cleaning: taking out a Dynabeads oligo (dT) 25 microsphere bottle, uniformly mixing by vortex, sucking enough microspheres according to 2 mu l/hole, placing on a magnet block, standing for 30s, discarding supernatant, and resuspending by using 500 mu l lysine Buffer;

(3) preparation: adding the microspheres into a 50mL centrifuge tube according to 9. Mu.l/hole lysine Buffer, adding the 500. Mu.l microsphere suspension, and uniformly blowing by using a gun;

(4) subpackaging: subpackaging the microspheres by using an eight-connecting tube, and then adding the microspheres into a cell plate according to 9 mu l/hole by using a discharge gun;

(5) rinsing: pasting a film on a 96-hole plate, then rinsing the periphery of the tube wall for 2 cycles;

(6) and (3) incubation: standing at room temperature for 5min to fully release mRNA of RBD specific memory B cells and combine the mRNA to the microspheres, and after the incubation is finished, performing 600 Xg instantaneous centrifugation to enable the microspheres to be centrifuged at the bottom of the hole. Place 96-well plates in DynaMag ^TM -96side Magnet magnetic plate, pipette off supernatant;

(7) wash A: adding Washing Buffer A according to 8 mul/hole, walking the plate back and forth for 7-8 times to fully wash the microspheres, and discarding the supernatant;

(8) wash B: wash Buffer B was added at 8. Mu.l/well, the plate was walked back and forth 7-8 times to wash the microspheres thoroughly, the supernatant was discarded, and then the pre-prepared Reverse Transcription (RT) reaction was added at 10. Mu.l/well. The reagent preparation and reaction conditions are described in the following (2).

(2) Reverse Transcription (RT) (10 μ l system): the reagents required for formulation are shown in table 1 below.

Name of reagent	Volume of
		DEPC-H ₂ O	4.5μl
5×primerscript Buffer	2.0μl
		2.5mM dNTP	2.0μl
RNase Inhibitor	1μl
		Sample	beads
PrimerScript ⅡRTase	0.5μl
		Total volume	10μl

Reaction conditions are as follows: 42 ℃ for 60min (mix every 20 min).

After the reaction was completed, the 96-well plate was instantaneously centrifuged at 600 Xg, and then the 96-well plate was placed on DynaMag ^TM On a 96-side Magnet magnetic plate, the supernatant was aspirated off by a discharge gun, and then a previously prepared TDT reaction solution was added at 10. Mu.l/well, and the reagent preparation and reaction conditions were as described in (3) below.

(3) Add G tail (TDT) (10. Mu.l system): the reagents required for formulation are shown in table 2 below.

Name of reagent	Volume of
		H ₂ O	6.4μl
5×TdT buffer	2.0μl
		10mM dGTP	0.5μl
0.1％BSA	1.0μl
		Sample	beads
TdT	0.1μl
		Total volume	10μl

The reaction conditions are as follows: 37 ℃ for 40min (every 20min mixing).

After the reaction, the reaction mixture was centrifuged at 600 Xg in a 96-well plate and then placed in DynaMag ^TM On a 96-side Magnet magnetic plate, the supernatant was aspirated off by a pipette, and then 10. Mu.l/well of a first PCR (1 st PCR) reaction solution prepared in advance was added thereto, and the reagents were prepared under the following conditionsThe description of (4) above.

(4) 1st PCR (10. Mu.l system) (see primer sequence Listing): the reagents required for formulation are shown in table 3 below:

name of reagent	Volume of
		H ₂ O	1.9μl
2×GC Buffer	5μl
		2.5mM dNTP	1μl
FP:AP3-dC(10μM)	0.5μl
		RP1:Cg-1st(10μM)	0.5μl
RP2:Ck-1st(10μM)	0.5μl
		RP3:CI-RT(10μM)	0.5μl
PrimesTAR	0.1μl
		sample	beads
Total volume	10μl

Based on the PCR principle, the experimental reaction conditions of 1st PCR are as follows: (1) pre-denaturation at 95 ℃ for 3min; (2) denaturation at 95 ℃ for 15sec, annealing at 60 ℃ for 5sec, elongation at 72 ℃ for 1min,30-35cycles, preferably 30cycles in this example; (3) extension is carried out for 5min at 72 ℃ in a circulating way, and the product is stored at 4 ℃.

(5) Second round PCR (2 nd PCR) (10. Mu.l system) (see primer sequence Listing one and primer sequence Listing two): the reagents required for formulation are shown in table 4 below:

name of reagent	Volume of
		H ₂ O	1.5μl
2×GC Buffer	5μl
		2.5mM dNTP	1μl
FP:MAC-AP3/AP3(10μM)	0.5μl
		RP:Cg-nest/K20/CI-nest(10μM)	0.5μl
PrimesTAR	0.5μl
		sample	1μl
Total volume	10μl

Based on the PCR principle, the experimental reaction conditions of 2nd PCR are as follows: (1) pre-denaturation at 95 ℃ for 3min; (2) denaturation at 95 ℃ for 15sec, annealing at 60 ℃ for 5s, elongation at 72 ℃ for 1min,30-35cycles, preferably 35cycles in this example; extension is carried out for 5min at 72 ℃ in a circulating way, and the product is stored at 4 ℃.

After the PCR is finished: mu.l of each well was subjected to 1.5% agarose gel electrophoresis. The cell pore paired with the Gamma chain and Kappa chain or Lamada chain was sequenced.

(6) Amplification and construction of antibody expression cassette (BCR-ORF): PCR amplification promoter region (CMV promoter), WPRE-gamma (antibody gamma chain) and WPRE-kappa (antibody kappa chain) the PCR amplification system is shown in Table 5 below.

The PCR amplification conditions were: (1) pre-denaturation at 95 ℃ for 3min; (2) denaturation at 95 ℃ for 15sec, annealing at 56 ℃ for 15sec, elongation at 72 ℃ for 1min,30cycles; (3) circulating at 72 deg.C for external extension of 5min, and storing at 12 deg.C.

(7) CMV, WPRE-gamma/kappa/l fragment amplification and CMV, BCR-Vgamma/kappa/l, WPRE-gamma/kappa/l Overlap PCR (Overlap PCR) pre-connection, the experimental system is shown in the following table 6.

/>

The PCR amplification conditions were: pre-denaturation at 95 ℃ for 3min; denaturation at 95 ℃ for 15sec, annealing at 50 ℃ for 15sec, elongation at 72 ℃ for 1.5min,10cycles; extension is carried out for 5min at 72 ℃ in a circulating way, and the product is stored at 12 ℃.

(8) BCR-gamma ORF, BCR-kappa ORF and BCR-l PCR amplification: the experimental system is shown in table 7 below.

PCR amplification procedure: pre-denaturation at 95 ℃ for 3min; denaturation at 95 ℃ for 15sec, annealing at 58 ℃ for 15sec, elongation at 72 ℃ for 1.5min,30cycles; circulating at 72 deg.C for external extension of 5min, and storing at 12 deg.C.

After amplification, agarose gel electrophoresis is adopted, and whether the size of the obtained antibody variable region gene is correct or not is analyzed by gel imaging, the experimental result is shown in figure 4, the Marker is in the middle position, and the strip is in the position of 5000 bp.

BCR-gamma ORF and BCR-kappa/ORF ethanol precipitation: respectively placing 30 mul of PCR products of BCR-gamma ORF and BCR-kappa ORF into an 8-connection tube, adding 120 mul of absolute ethyl alcohol and 6 mul of sodium acetate solution, fully and uniformly mixing, and standing for 30min at-80 ℃;10000rpm, centrifuging for 20min, discarding the supernatant, sequentially rinsing with 200 μ l of 70% ethanol and anhydrous ethanol once respectively, fully volatilizing the ethanol at 56 deg.C, adding 40 μ l of sterile water, oscillating to fully dissolve the precipitate, and detecting the concentration of antibody variable region gene.

The Leader primers used in S3 and S4 are described in the following primer sequence I:

/>

the J-region primers used for S3 and S4 are described in the following primer sequence Listing:

/>

and S5, transducing the antibody variable region gene expression cassette obtained in the S4 into 293T cells for 48 hours to express the antibody, collecting the supernatant, detecting the RBD specificity of the supernatant by using an ELISA method, and screening the RBD specific fully human monoclonal antibody.

(A) Antigen was diluted with PBS (final concentration 2. Mu.g/mL), 10. Mu.l/well, and coated onto 384-well ELISA plates overnight at 4 ℃ or 2h at 37 ℃ (4 ℃ overnight is preferred in this example). NOTE: after the addition, the liquid is instantly centrifuged to ensure that the liquid is at the bottom.

The experimental system is shown in table 8 below:

name of reagent	Goods number	Original concentration	Final concentration	Dilution ratio
					SARS-COV-2RBD	Cat:40592-V08H	200μg/mL	2μg/mL	1:100
GoatpabtoHuIgG－ALP	Cat:ab97221	1mg/mL	2μg/mL	1:500

(B) PBST (0.05% Tween 20, cat #, TB220) was prepared: 1L of PBS was added with 0.5mL of Tween 20;

PBST machine washed plates (Thermoscientific wellwash versa) or hand washed (plates that were machine washed were still manually clapped/centrifuged using a microplate centrifuge (MPC-P25) for 1min to make the plates invisible to water and air bubbles).

And (3) sealing: 80 μ l of BSA (BioFroxx, cat. NO:4240GR 100) at 5% (prepared in PBST) was added to the washed plate and incubated at 37 ℃ for 1 hour in an incubator. PBST machine washing board or hand washing.

(C) Sample adding and standard substance. Wherein, the standard substance: 10 μ l/well stock concentration 1 μ g/mL, gradient dilutions 250ng/mL, 125ng/mL, 62.5ng/mL, 31.25ng/mL, 15.63ng/mL, 7.81ng/mL, 3.9ng/mL, and 1.95ng/mL. (dilution of blocking solution); sample preparation: cell supernatants transfected with antibody genes. Negative control/blank wells: blocking solution 10. Mu.l/well.

Incubate at 37 ℃ for 30min. PBST machine washing board or hand washing.

(D) Secondary antibody was added at a concentration of 10. Mu.l/well, followed by incubation at 37 ℃ for 30min.

The experimental system is shown in table 9 below:

PBST machine washing board or hand washing. Mu.l/well of PNPP (disodium p-nitrophenylphosphate) and OD (450 mm) values of 5min,10 min, 15min, 20min, 25min, 30min, 35min, 40min, 45min, 50min, 55min and 60min were measured using (Thermoscientific Muttiskan GO). 50mg PNPP powder (Thermo, prod # 34045) +40mL ddH ₂ O +10mL of Diethylhanol amine substrate Buffer (5X), and PNPP was stored at 4 ℃ protected from light.

The results are shown in FIG. 5, and FIG. 5 shows that the OD value greater than 0.1 is positive.

The foregoing is merely a preferred embodiment of this invention, which is intended to be illustrative, not limiting; it will be appreciated by those skilled in the art that many changes, modifications and equivalents can be made thereto within the spirit and scope of the invention as defined by the appended claims and all such modifications and equivalents fall within the scope of the invention.

Claims

1. The novel coronavirus RBD specific monoclonal antibody is characterized in that the heavy chain amino acid sequence is shown as SEQ ID NO. 1; the light chain amino acid sequence is shown as SEQ ID NO. 2.

2. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 3; the light chain amino acid sequence can also be shown as SEQ ID NO. 4.

3. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 5; the light chain amino acid sequence can also be shown as SEQ ID NO 6.

4. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 7; the light chain amino acid sequence can also be shown as SEQ ID NO. 8.

5. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 9; the light chain amino acid sequence can also be shown as SEQ ID NO. 10.

6. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further represented by SEQ ID No. 11; the light chain amino acid sequence can also be shown as SEQ ID NO 12.

7. The novel coronavirus RBD-specific monoclonal antibody of claim 1 wherein the heavy chain amino acid sequence is further defined as SEQ ID No. 13; the light chain amino acid sequence can also be shown as SEQ ID NO. 14.

8. The novel coronavirus RBD-specific monoclonal antibody of claim 1, wherein the heavy chain amino acid sequence is further as set forth in SEQ ID No. 15; the light chain amino acid sequence can also be shown as SEQ ID NO 16.

9. The novel coronavirus RBD specific monoclonal antibody according to any one of claims 1-8, wherein the antibody variable region cDNA is obtained from the mRNA of an RBD specific memory B cell by sorting the RBD specific memory B cell.

10. Nucleic acid molecule encoding a novel coronavirus RBD specific monoclonal antibody according to any one of claims 1-8.